Clinical Trial

Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Name: Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC — clinical trial record (NCT07540832)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.

Trial Details

NCT Number	NCT07540832
Lead Sponsor	Zhejiang Haichang Biotech Co., Ltd.
Conditions	Advanced Hepatocellular Carcinoma (HCC)
Enrollment	80 participants
Start Date	2026-09
Primary Completion	2028-09 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-20